ストックスクリーナーアプリを入手
1.85
2.78%
0.05
アフターアワーズ：
1.90
0.05
+2.70%
前日終値:
$1.80
開ける：
$1.78
24時間の取引高:
751.47K
Relative Volume:
3.21
時価総額：
$111.15M
収益：
-
当期純損益:
$-64.86M
株価収益率:
-1.6228
EPS:
-1.14
ネットキャッシュフロー:
$-55.66M
1週間 パフォーマンス:
-8.87%
1か月 パフォーマンス:
-21.94%
6か月 パフォーマンス:
-16.29%
1年 パフォーマンス:
-39.94%
1日の値動き範囲:
$1.75
$1.86
1週間の範囲:
$1.715
$2.0299
52週間の値動き範囲:
$1.715
$5.09
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
名前
Acumen Pharmaceuticals Inc
セクター
電話
925-368-8508
住所
427 PARK ST., CHARLOTTESVILLE
ABOS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.85 | 111.15M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-26 | 開始されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-20 | 再開されました | BofA Securities | Buy |
| 2023-05-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-07-15 | 開始されました | BTIG Research | Buy |
| 2022-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-07-26 | 開始されました | BofA Securities | Neutral |
| 2021-07-26 | 開始されました | Credit Suisse | Outperform |
| 2021-07-26 | 開始されました | Stifel | Buy |
| 2021-07-26 | 開始されました | UBS | Buy |
すべてを表示
Acumen Pharmaceuticals Inc (ABOS) 最新ニュース
Acumen stock touches 52-week low at $1.9 amid market challenges - Investing.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
ABOS stock touches 52-week low at $2.08 amid market challenges - Investing.com Australia
ABOS stock touches 52-week low at $2.08 amid market challenges By Investing.com - Investing.com South Africa
Contrasting Acumen Pharmaceuticals (NASDAQ:ABOS) and Genetic Technologies (NASDAQ:GENE) - Defense World
I-Mab Leads Our Spotlight On 3 US Penny Stocks - Simply Wall St
Halozyme to Present at Upcoming Investor Conferences - Finansavisen
ABOSAcumen Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference - The Manila Times
Acumen Pharmaceuticals to Present Alzheimer's Treatment Progress at Evercore Conference | ABOS Stock News - StockTitan
HC Wainwright Has Bearish Estimate for ABOS FY2024 Earnings - MarketBeat
Analyzing Ginkgo Bioworks (NYSE:DNA) & Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Aurora Cannabis Inc. (NASDAQ:ACB) Sees Large Increase in Short Interest - Defense World
HC Wainwright Reiterates “Buy” Rating for Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Catalent, Inc. (NYSE:CTLT) Shares Sold by Farther Finance Advisors LLC - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Given Buy Rating at HC Wainwright - MarketBeat
Earnings call: Acumen Pharmaceuticals reports on Q3 2024 progress - Investing.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Acumen Pharmaceuticals reports on Q3 2024 progress By Investing.com - Investing.com UK
Acumen Pharmaceuticals Advances Alzheimer’s Therapeutic - TipRanks
Acumen Pharmaceuticals' Shares Drop on Wider 3Q Loss - MarketWatch
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Acumen Reports $258.9M Cash Runway Despite Widening Q3 Loss; Alzheimer's Trial Advances | ABOS Stock News - StockTitan
Earnings Scheduled For November 12, 2024 - Benzinga
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference - The Manila Times
Acumen Pharma to Present Alzheimer's Treatment Progress at Stifel Healthcare Conference | ABOS Stock News - StockTitan
Acumen Pharma announces new appointment | Biotechnology | The Pharmaletter - The Pharma Letter
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference - The Manila Times
Acumen Pharma to Present Alzheimer's Treatment Progress at UBS Healthcare Conference | ABOS Stock News - StockTitan
Acumen Pharmaceuticals (ABOS) Scheduled to Post Earnings on Tuesday - MarketBeat
Acumen Pharmaceuticals appoints new regulatory chief - Investing.com
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality - The Manila Times
Acumen Pharma Taps Former Sage Executive to Lead Alzheimer's Drug Development | ABOS Stock News - StockTitan
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - WICZ
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference - The Manila Times
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference - StockTitan
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS - PR Newswire
Uipath Inc Cl A (PATH-N) QuotePress Release - The Globe and Mail
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Decrease in Short Interest - MarketBeat
National Bank Financial Forecasts TSE:BIP Q3 Earnings - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 18.6% in October - Defense World
Finance/Insurance: PAUL B. MANNING - Virginia Business Magazine
Acumen reveals Alzheimer's trial screening method By Investing.com - Investing.com Australia
Halozyme to Report Third Quarter 2024 Financial and Operating Results - The Malaysian Reserve
Acumen reveals Alzheimer's trial screening method - Investing.com India
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - The Manila Times
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on - The Bakersfield Californian
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
Acumen Pharmaceuticals Inc (ABOS) 財務データ
収益
当期純利益
現金流量
EPS
Acumen Pharmaceuticals Inc (ABOS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 19 '24 |
Sale |
3.48 |
8,933 |
31,048 |
108,867 |
| Zuga Matt | CFO & Chief Business Officer |
Jan 18 '24 |
Sale |
3.71 |
4,242 |
15,717 |
211,445 |
| Siemers Eric | Chief Medical Officer |
Jan 18 '24 |
Sale |
3.71 |
3,124 |
11,604 |
117,576 |
| Barton Russell | Chief Operating Officer |
Jan 18 '24 |
Sale |
3.73 |
2,833 |
10,555 |
96,867 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):